RenovoRx (RNXT) FCF Margin (2025 - 2026)

RenovoRx (RNXT) posted FCF Margin of 658.79% for Q1 2026, up 48.08% sequentially from 1268.91% in Q4 2025, and up 105745.0% YoY from N/an in Q1 2025.

RenovoRx (RNXT) FCF Margin (2025 - 2026) Analysis & Trends

RenovoRx has reported FCF Margin for 2 years, with the latest figure at 658.79% in Q1 2026.

Quarterly FCF Margin rose 105745.0% year-over-year to 658.79% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 759.1% (changed N/A YoY) and the FY2025 annual result came in at 977.29%, up 2027154.0% from the prior year.
FCF Margin grew to 658.79% in Q1 2026 per RNXT's latest filing, from 1268.91% in the prior quarter.
Over five years, FCF Margin peaked at 545.97% in Q2 2025 and troughed at 1716.24% in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Vertex Pharmaceuticals	140.22 Bn	132.37 Bn	2.84 Bn	30.39%
2	Regeneron Pharmaceuticals	86.29 Bn	78.30 Bn	3.93 Bn	13.35%
3	Argenx Se	65.17 Bn	59.98 Bn	1.37 Bn	-
4	Moderna	61.38 Bn	56.24 Bn	52.00 Mn	-388.28%
5	BeOne Medicines	42.18 Bn	37.09 Bn	1.53 Bn	25.68%
6	Alnylam Pharmaceuticals	30.99 Bn	27.68 Bn	992.69 Mn	22.62%
7	BioNTech SE	28.45 Bn	10.05 Bn	668.28 Mn	41.07%
8	Insmed	27.47 Bn	26.31 Bn	358.27 Mn	-22.35%
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	70.82%
10	RenovoRx	59.83 Mn	59.83 Mn	766,000.00	-337.40%

Download Data